Health economic assessment of Tecentriq for triple negative breast cancer


8 November 2019 - TLV has produced a health economic knowledge base for the county council for the drug Tecentriq (atezolizumab). 

The knowledge base evaluates Tecentriq in combination with nab-paclitaxel for the treatment of adult patients with non-resectable locally advanced or metastatic triple-negative breast cancer with tumours that have a PD-L1 expression ≥ 1% and have not previously received metastatic cell donation. disease.

There are several uncertainties in the evaluation. One such is the lack of long-term data on how long patients treated with Tecentriq in combination with nab-paclitaxel survive.

Read TLV News [Swedish]

Michael Wonder

Posted by:

Michael Wonder